Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Justin Hayase , Duc H Do , Noel G Boyle Added: 3 years ago
The ICD is an important therapy for both primary and secondary prevention of sudden cardiac death in selected patients. The role for defibrillation threshold (DFT) testing either intraoperatively or postoperatively has changed significantly over the past few decades, and it is no longer routinely recommended in patients undergoing left-sided transvenous ICD implantation.1–7 The definition of the… View more
Author(s): Dietmar Bänsch Added: 3 years ago
For more than three decades, the implantable cardioverter defibrillator (ICD) has proven to be a well-established, main therapeutic tool for the primary and secondary prevention of sudden cardiac death due to malignant ventricular arrhythmias.1 One of the standard practice concepts is defibrillation (DF) testing. Defibrillation testing has been considered a mandatory part at the time of… View more
Research Area(s) / Expertise:

Atrial Fibrillation

Pacing, Defibrillators & Cardiac Resynchronisation Therapy

Job title: Consultant Cardiac Electrophysiologist
John qualified from University of Southampton in 1997 and completed his research and clinical training in Southampton and Oxford. He practices in all aspects of ablation and devices and has research interests across these areas. He is chair of the BHRS Education Committee and Vice Chair of the Cardiology Specialty Advisory Committee View more
Author(s): Jaber Abboud , Joachim R Ehrlich Added: 3 years ago
Implantable cardioverter defibrillators (ICDs) have been used for over 30 years to prevent sudden cardiac death (SCD). The first indications for ICD placement were secondary prevention; later trials demonstrated a primary prevention benefit of ICD therapy in patients at risk of SCD. ICD therapy prolongs life in both patient populations.1 However, the efficacy of an ICD depends on its ability to… View more
Jeff Healey serves as the director of arrhythmia services and holds the position of associate professor of medicine at McMaster University in Hamilton, Ontario, Canada. As a clinical trialist and member of the Population Health Research Institute, Dr. Healey completed his clinical training in cardiology and electrophysiology at the University of Ottawa Heart Institute. He furthered his academic… View more
Author(s): Marco Bergonti Added: 1 year ago
EHRA 23 - Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial. In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF… View more
Author(s): Hussam Ali , Pierpaolo Lupo , Riccardo Cappato Added: 3 years ago
Numerous large clinical trials have demonstrated the benefit of implantable cardioverter-defibrillators (ICDs) to prevent sudden cardiac death (SCD) in selected populations.1,2 These results and advances in defibrillation therapies have led to an impressive expansion of ICD implants and indications in recent decades. Although initially focusing on secondary prevention, current ICD indications… View more